Headlands Research, a portfolio company of KKR, announced on May 4 that it entered into an agreement to acquire Clinvest Research. According to data captured in the LevinPro HC database, this acquisition marks the 10th clinical trials transaction of the year.
Founded in 1996, Clinvest Research has conducted more than 600 trials for chronic diseases and conditions such as headaches/migraines, arthritis and chronic pain and diabetes, as well as weight loss.
Headlands is a globally integrated clinical trial site organization. The company has successfully completed more than 5,000 clinical trials. It was founded in 2018 and has 15 offices across the United States.
The acquisition of Clinvest Research strengthens Headlands Research’s chronic pain and endocrinology expertise and increases participant access to clinical trials for prevalent diseases and conditions that often remain undiagnosed. The financial terms were not disclosed.
